ERBB2 and breast carcinoma: The activation of IGF2/IGF-1R/IRS1 signaling is one of the key mechanisms underlying anti-HER2 resistance in breast cancer, with this activation occurring through the AKT/mTOR pathway, which in turn activates Src kinase.